PureTech Health (LON:PRTC) Trading 14.2% Higher - Should You Buy?

Key Points

• PureTech Health plc's share price increased by 14.2%, with a trading volume surge of 1,053% compared to the average during a recent trading session.
• The company has a market capitalization of £293.65 million and a P/E ratio of 714.71, indicating very high valuation metrics.
• Recent insider activity saw Bharatt Chowrira purchase 167,739 shares at an average cost of GBX 1 per share, enhancing insider confidence.

PureTech Health plc (LON:PRTC - Get Free Report) traded up 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 14.2%

The business has a fifty day moving average of GBX 129.46 and a 200 day moving average of GBX 129.76. The firm has a market cap of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82.

Insider Activity

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction on Thursday, July 3rd. The stock was bought at an average cost of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is owned by company insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.